Access Pharmaceuticals begins dosing in phase 2 study of ProLindac in ovarian cancer

By Lisa Kerner

Charlotte, N.C., June 8 - Access Pharmaceuticals Inc. said it began the first company-sponsored phase 2 clinical study of ProLindac, a novel DACH platinum-polymer prodrug, in the treatment of ovarian cancer, with the dosing of the first patient in France.

The open-label trial is being conducted in Europe and managed by Cvitkovic and Associates.

"In our phase 1 trial, there were two responses in ovarian patients who had relapsed after prior cis- or carboplatin therapy," chief executive officer Rosemary Mazanet said in a company news release.

"Given these promising early results for ProLindac, we are now eager to see what the response rate will be in a larger study at a phase 2 dose."

The company said it expects interim results from the study by the end of the year and additional clinical trials in other cancers are planned.

Dallas-based Access is an emerging biopharmaceutical company specializing in propriety products for the treatment and supportive care of cancer patients.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.